A Study of MEDI9253 in combination with durvalumab in select solid tumors

Study identifier:D7880C00001

ClinicalTrials.gov identifier:NCT04613492

EudraCT identifier:2020-002294-96

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors

Medical condition

Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

37

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 02 Dec 2020
Estimated Primary Completion Date: 26 Nov 2024
Estimated Study Completion Date: 26 Nov 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria